Skip to main content

Advertisement

SpringerLink
Log in

Mantle cell lymphoma: Frontline and salvage therapy

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Mantle cell lymphoma (MCL) is a therapeutic challenge because of its lower cure rate when compared with other lymphomas such as diffuse large cell lymphoma. The current emphasis in the treatment of newly diagnosed MCL has been on intensifying chemotherapy, but there is no consensus on the need to consolidate with autologous stem cell transplantation. These approaches, however, have not resulted in a cure. Newer strategies include the use of models to aid in tailoring therapy. Likewise, autologous stem cell consolidation does not cure relapsed disease. Because of its known graft-versus-lymphoma effect, allogeneic stem cell transplantation offers a potentially curative option for relapsed MCL. New insights into resistance pathways and new drugs created to inhibit them offer great promise in the treatment of newly diagnosed and previously treated MCL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Meusers P, Hense J, Brittinger G: Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems. Leukemia 1997, 11(Suppl 2):S60–S64.

    PubMed  Google Scholar 

  2. Harris NL, Jaffe ES, Diebold J, et al.: The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000, 36:69–86.

    Article  PubMed  CAS  Google Scholar 

  3. Jares P, Colomer D, Campo E: Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007, 7:750–762.

    Article  PubMed  CAS  Google Scholar 

  4. Hoster E, Dreyling M, Klapper W, et al.: A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008, 111:558–565.

    Article  PubMed  CAS  Google Scholar 

  5. Romaguera JE, Fayad L, Rodriguez MA, et al.: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005, 23:7013–7023.

    Article  PubMed  CAS  Google Scholar 

  6. Tiemann M, Schrader C, Klapper W, et al.: Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005, 131:29–38.

    Article  PubMed  Google Scholar 

  7. Rosenwald A, Wright G, Wiestner A, et al.: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185–197.

    Article  PubMed  CAS  Google Scholar 

  8. Determann O, Hoster E, Ott G, et al.: Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008, 111:2385–2387.

    Article  PubMed  CAS  Google Scholar 

  9. Lenz G, Dreyling M, Hoster E, et al.: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005, 23:1984–1992.

    Article  PubMed  CAS  Google Scholar 

  10. Schultz H, Bohlius JF, Trelle S, et al.: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007, 99:706–714.

    Article  Google Scholar 

  11. Fayad LE, Thomas DA, Romaguera JE: Update of the M.D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma 2007, 8(Suppl 2):S57–S62.

    Article  PubMed  CAS  Google Scholar 

  12. Kahl, BS, Longo WL, Eickhoff JC, et al.: Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006, 17:1418–1423.

    Article  PubMed  CAS  Google Scholar 

  13. Lefrere F, Delmer A, Suzan F, et al.: Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002, 16:587–593

    Article  PubMed  CAS  Google Scholar 

  14. Ganti AK, Bierman PJ, Lynch JC, et al.: Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005, 16:618–624.

    Article  PubMed  CAS  Google Scholar 

  15. Gianni AM, Magni M, Martelli M, et al.: Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003, 102:749–755.

    Article  PubMed  CAS  Google Scholar 

  16. Andersen NS, Pedersen LB, Laurell A, et al.: Successful preemotive treatment of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma [abstract 1281]. Blood 2007, 110:386a.

    Google Scholar 

  17. Dreyling M, Lenz G, Hoster E, et al.: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005, 105:2677–2684.

    Article  PubMed  CAS  Google Scholar 

  18. Khouri IF, Saliba RM, Okoroji GJ, et al.: Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003, 98:2630–2635.

    Article  PubMed  Google Scholar 

  19. DeGuibert S, Jaccard A, Bernard M, et al.: Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica 2006, 91:425–426.

    CAS  Google Scholar 

  20. Geisler CH, Elonen E, Kolstad A, et al.: Mantle cell lymphoma can be cured by intensive immunochemotherapy with in-vivo purged stem-cell support; final report of the Nordic Lymphoma Group MCL2 Study [abstract 1]. Blood 2007, 110:LB1.

    Google Scholar 

  21. Khouri IF, Lee MS, Saliba RM, et al.: Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003, 21:4407–4412.

    Article  PubMed  CAS  Google Scholar 

  22. Ghielmini M, Schmitz SF, Cogliatti S, et al.: Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005, 23:705–711.

    Article  PubMed  CAS  Google Scholar 

  23. Forstpointner R, Unterhalt M, Dreyling M, et al.: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006, 108:4003–4008.

    Article  PubMed  CAS  Google Scholar 

  24. Pott C, Schrader C, Gesk S, et al.: Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006, 107:2271–2278.

    Article  PubMed  CAS  Google Scholar 

  25. Zinzani PI, Magagnoli M, Moretti L, et al.: Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol 2000, 18:773–779.

    PubMed  CAS  Google Scholar 

  26. Decaudin D, Bosq J, Munck JN, et al.: Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 1998, 16:579–583.

    PubMed  CAS  Google Scholar 

  27. Cohen BJ, Moskowitz C, Straus D, et al.: Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001, 42:1015–1022.

    Article  PubMed  CAS  Google Scholar 

  28. Foran JM, Rohatiner AZ, Coiffier B, et al.: Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström’s macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999, 17:546–553.

    PubMed  CAS  Google Scholar 

  29. Rummel MJ, Von Gruenhagen U, Niederle N, et al.: Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas — first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract 385]. Blood 2007, 110.

  30. Vandenberghe E, Ruiz de Alvire C, Loberiza FR, et al.: Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003, 120:793–800.

    Article  PubMed  Google Scholar 

  31. Gopal AK, Rajendran JG, Petersdorf SH, et al.: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002, 99:3158–3162.

    Article  PubMed  CAS  Google Scholar 

  32. Forstpointner R, Dreyling M, Repp R, et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064–3071.

    Article  PubMed  CAS  Google Scholar 

  33. Fisher RI, Bernstein SH, Kahl BS, et al.: Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006, 24:4867–4874.

    Article  PubMed  Google Scholar 

  34. Drach J, Kaufmann H, Pichelmayer O, et al.: Bortezomib, rituximab, and dexamethasone (BORID) as salvage treatment in relapsed/refractory mantle cell lymphoma: sustained disease control in patients achieving a complete remission [abstract 2578]. Blood 2007, 110.

  35. Kaufmann H, Raderer M, Wöhrer S, et al.: Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004, 104:2269–2271.

    Article  PubMed  CAS  Google Scholar 

  36. Wang M, Fayad LE, Hagemeister FB, et al.: Lenalidomide (Len) in combination with rituximab (R) demonstrated early evidence of efficacy in a phase I/II study in relapsed/refractory mantle cell lymphoma (MCL) [abstract 2562]. Blood 2007, 110.

  37. Hess G, Romaguera JE, Verhof G, et al.: Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator’s choice therapy [abstract 8513]. ASCO Proc 2008.

  38. Rodriguez J, Gutierrez A, Palacios A, et al.: Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk Lymphoma 2007, 48:2172–2178.

    Article  PubMed  CAS  Google Scholar 

  39. Robak T, Lech-Maranda E, Janus A, et al.: Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin’s lymphoma. Leuk Lymphoma 2007, 48:1092–1101.

    Article  PubMed  CAS  Google Scholar 

  40. Rummel MJ, Al-Batran SE, Kim SZ, et al.: Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol 2005, 23:3383–3389.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Lymphoma/Myeloma, Unit 429, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

    Jorge E. Romaguera

Authors
  1. Jorge E. Romaguera
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jorge E. Romaguera.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Romaguera, J.E. Mantle cell lymphoma: Frontline and salvage therapy. Curr Hematol Malig Rep 3, 204–209 (2008). https://doi.org/10.1007/s11899-008-0029-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-008-0029-3

Keywords

Search

Navigation